{"id":9864,"date":"2025-03-20T06:06:15","date_gmt":"2025-03-20T10:06:15","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=9864"},"modified":"2025-03-20T06:06:15","modified_gmt":"2025-03-20T10:06:15","slug":"opko-entera-enter-partnership-to-develop-obesity-pill","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/opko-entera-enter-partnership-to-develop-obesity-pill\/","title":{"rendered":"Opko &#038; Entera Enter Partnership to Develop Obesity Pill"},"content":{"rendered":"<p>Opko Health and Entera Bio have formally announced their collaboration as the biopharmaceutical companies seek to advance the first orally given dual agonist glucagon-like peptide 1 (GLP-1)\/glucagon peptide into clinical trials.<\/p>\n<p>The once-daily tablet integrates Opko\u2019s powerful GLP-1\/glucagon dual agonist peptide, known as OPK-88006, via Entera\u2019s N-Tab administration technology. The firms&#8217; present schedule includes requesting FDA authorization later this year to commence human studies, as stated in a statement dated March 17.<\/p>\n<p>The deal stipulates that Miami&#8217;s Opko and Israeli Entera will have 60% and 40% ownership, respectively, in the initiative, and will share the development expenditures in the same proportion.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nOpko will acquire 3.6 million shares of Entera for $2.17 each, somewhat above the $1.88 closing price after Friday&#8217;s trading session. Entera will use the income to finance its portion of the development expenses leading up to the phase 1 study.<\/p>\n<p>Subsequent to the first human trial, Entera will have the opportunity to further finance its portion of the research to maintain its stake in the program&#8217;s ownership. If the biotech chooses to withdraw at this juncture, it will retain a 15% ownership stake, while Opko would have the remaining 85% and assume the whole responsibility for research and finance.<\/p>\n<p>The two prominent obesity medications already available are Novo Nordisk\u2019s GLP-1 agonist Wegovy and Eli Lilly\u2019s combination GLP-1\/GIP agonist Zepbound. Currently, there are no licensed medicines that use Opko&#8217;s approach of concurrently stimulating the GLP-1 and glucagon receptors.<\/p>\n<p>The big pharmaceutical companies have focused on assessing dual GLP-1\/glucagon co-agonists as prospective therapies for metabolic dysfunction-associated steatohepatitis (MASH). AstraZeneca is developing its candidate, AZD9550, now in its first phase for liver disease, whereas Merck &#038; Co.\u2019s efinopegdutide outperformed Wegovy in a phase 2 study for nonalcoholic fatty liver disease.<\/p>\n<p>Opko said that introducing their medicine in the clinic this year would be the first instance of an orally given GLP-1\/glucagon agonist undergoing human testing. The expectation is that the medication may serve as a once-daily tablet therapy for those with obesity, metabolic problems, and fibrotic conditions.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nOpko and Entera have already been working together on an obesity medication and an oral GLP-2 peptide tablet, which they anticipate will provide an injection-free option for individuals with unusual malabsorption disorders, including short bowel syndrome.<\/p>\n<p>\u201cWe are pleased to continue working with Entera on this promising program to develop the first oral GLP-1\/glucagon dual agonist in addition to our subcutaneous injectable dual agonist GLP-1\/glucagon program,\u201d Phillip Frost, M.D., Onko\u2019s CEO, stated in the release. \u201cOur goal with this franchise is to provide additional options for patients with obesity, metabolic and fibrotic diseases.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Opko Health and Entera Bio have formally announced their collaboration as the biopharmaceutical companies seek to advance the first orally given dual agonist glucagon-like peptide 1 (GLP-1)\/glucagon peptide into clinical trials. The once-daily tablet integrates Opko\u2019s powerful GLP-1\/glucagon dual agonist peptide, known as OPK-88006, via Entera\u2019s N-Tab administration technology. The firms&#8217; present schedule includes requesting [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9867,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-9864","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/9864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=9864"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/9864\/revisions"}],"predecessor-version":[{"id":9868,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/9864\/revisions\/9868"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/9867"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=9864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=9864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=9864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}